A Phase 3b, Single-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-risk Adults

Trial Profile

A Phase 3b, Single-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-risk Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary)
  • Indications Meningococcal infections; Meningococcal meningitis
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 01 Dec 2014 Status changed from suspended to completed, according to ClinicalTrials.gov record.
    • 10 Jul 2014 Planned End Date changed from 1 Jan 2016 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
    • 03 Aug 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2011-003694-29).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top